✓ Medically reviewed by Dr. Anjmun Sharma, MD · Updated 2026-05-10

When Compounded GLP-1 Medication May Be Considered

Name: Why We Choose to Compound, Our Clinical Rationale
Published: 2026-05-10

The fair answer is not that compounded medication is always better or always worse. It is an option that may be considered for an identified patient only after medical review, a discussion of alternatives, and confirmation that the prescription is clinically appropriate.

The short version. Compounded semaglutide and tirzepatide are not FDA-approved and are not brand-identical. They may be considered only after physician review. The decision should account for medical history, access, dosing needs, cost, pharmacy standards, and the availability of an FDA-approved option. Results vary.

1. Patient-specific clinical review

A compounded prescription is written for an identified patient when the physician determines that it is permitted and clinically appropriate. A quiz can organize information, but it cannot establish eligibility. The medical history, current medications, contraindications, treatment goals, and follow-up plan all matter.

2. Dosing and follow-up

Dose changes should be based on response and tolerability, not a promise of faster weight loss. A compounded vial can support patient-specific dosing when appropriate, but that does not make the product FDA-approved, safer, or equivalent to a brand-name medication. Follow-up should include side-effect review, nutrition, hydration, progress, and a plan for holding or changing treatment when needed.

3. Pharmacy standards and documentation

When compounded medication is prescribed, fulfillment is through a state-licensed compounding pharmacy operating under section 503A. Patients should know which pharmacy dispenses the medication and may ask that pharmacy what lot, testing, storage, and beyond-use documentation is available. Documentation varies by pharmacy and product, so it should not be promised before it is confirmed.

4. B12 and lipotropic services are separate

B12 and lipotropic injections are not included in the $199 trial. They may be offered separately when clinically appropriate, with formulation and pricing reviewed during consultation. They should not be presented as guaranteed energy or weight-loss enhancers.

5. Clear total cost

The useful comparison is the full cost of each realistic option, including the physician review, medication, follow-up, labs when needed, and any insurance requirements. Our pricing page separates the $119 physician review from medication pricing and explains what the $199 one-month semaglutide trial includes. Current terms should be confirmed before purchase.

6. When an FDA-approved brand medication may be preferable

If an FDA-approved medication is accessible, clinically appropriate, and affordable, it deserves a direct comparison. Coverage, supply, dosing format, side effects, and patient preference can change the answer. We do not use a blanket rule that compounded medication is the right choice for everyone.

What we will not claim

We will not claim brand equivalence. Compounded semaglutide and tirzepatide are not brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality.
We will not prescribe without physician review. Every new prescription and refill requires clinical authorization.
We will not promise a specific result. Response, side effects, and weight change vary from person to person.
We will not promise pharmacy documentation we have not confirmed. Patients may ask the dispensing pharmacy what records are available for their product and lot.

What this means for you

The two-minute quiz is a screening step, not a medical decision. Continue to the medical intake so the physician can compare options, explain material risks and limitations, and determine whether treatment is appropriate for you.

This page is informational only and not medical advice. Speak with a licensed physician before starting any GLP-1 therapy. Individual results vary. If a compounded prescription is considered, the dispensing pharmacy's identity, license, legal authority, and ability to fulfill for the patient and location must be verified before fulfillment. We do not dispense Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary. Any prescription depends on individualized medical review and lawful pharmacy fulfillment for the patient's location. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by these companies.